Trials / Completed
CompletedNCT06161090
Study of CM310 in Healthy Subjects
Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM310 Recombinant Humanized Monoclonal Antibody Injection in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a single center, randomized, double-blind, placebo-controlled, dose escalation study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM310 | CM310 injection |
| DRUG | Placebo | subcutaneous injection |
Timeline
- Start date
- 2019-09-03
- Primary completion
- 2020-01-13
- Completion
- 2020-01-13
- First posted
- 2023-12-07
- Last updated
- 2023-12-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06161090. Inclusion in this directory is not an endorsement.